Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
Recruiting
N/A
Interventional Study
Diabetes Mellitus, Type 2
Cardiovascular Diseases
Diabetic Nephropathy Type 2
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 2,714 (estimated)
- Sponsor
- Optithera · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these complications achieve over an 18 months period, recommended therapeutic targets.
This will be demonstrated as a significant improvement in a composite value including HbA1c or systo…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patients with T2D of both sexes regardless of ethnicity, level of diabetes control and presence of complications.
* Able to visit the study site 7 times
* Able and willing to provide informed consent to the clinical and PRS parts of the study.
Exclusion Criteria:
* Any…
Contacts